Vera Therapeutics Reports Third Quarter 2026 Financial Results and Business Update

Vera Therapeutics reported $10.3 million in net product revenue for the third quarter ended September 30, 2026. Its U.S. launch of TRUTAKNA, which received FDA accelerated approval on July 7, generated approximately 700 Patient Start Forms to date. The final ORIGIN 3 analysis showed a 76% lower risk of composite kidney disease progression versus placebo over two years, and Vera submitted an sBLA seeking full FDA approval for TRUTAKNA in adults with primary IgAN.